Last update 20 Mar 2025

IMC-I109V

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
ImmTAV-Env
Action
stimulants, inhibitors
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HBsAg inhibitors(HBsAg inhibitors)
Active Indication
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis B, ChronicPhase 1
United Kingdom
12 Aug 2020
Hepatitis B, ChronicPhase 1
Spain
12 Aug 2020
Hepatitis B, ChronicPhase 1
Denmark
12 Aug 2020
Hepatitis B, ChronicPhase 1
United States
12 Aug 2020
Hepatitis B, ChronicPhase 1
Romania
12 Aug 2020
Hepatitis B, ChronicPhase 1
South Korea
12 Aug 2020
Hepatitis B, ChronicPhase 1
Australia
12 Aug 2020
Hepatitis B, ChronicPhase 1
Taiwan Province
12 Aug 2020
Hepatitis B, ChronicPhase 1
Hong Kong
12 Aug 2020
Hepatitis BPhase 1
Belgium
04 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
3
(wrzkkwgddy) = decreased by 11-15% during Days 3-15 post infusion ylqtbatwsr (gogfhxgqcr )
Positive
25 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free